Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.
Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Vathiotis IA, et al. Among authors: sotiriou c. Clin Cancer Res. 2021 Nov 15;27(22):6156-6163. doi: 10.1158/1078-0432.CCR-21-2103. Epub 2021 Aug 31. Clin Cancer Res. 2021. PMID: 34465600 Free PMC article.
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D. Durbecq V, et al. Among authors: sotiriou c. Mol Cancer Ther. 2004 Oct;3(10):1207-14. Mol Cancer Ther. 2004. PMID: 15486187 Clinical Trial.
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F. Giuliani R, et al. Among authors: sotiriou c. Eur J Cancer. 2007 Mar;43(4):725-35. doi: 10.1016/j.ejca.2006.11.019. Epub 2007 Jan 23. Eur J Cancer. 2007. PMID: 17251007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF. Gong Y, et al. Among authors: sotiriou c. Lancet Oncol. 2007 Mar;8(3):203-11. doi: 10.1016/S1470-2045(07)70042-6. Lancet Oncol. 2007. PMID: 17329190
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Loi S, et al. Among authors: sotiriou c. J Clin Oncol. 2007 Apr 1;25(10):1239-46. doi: 10.1200/JCO.2006.07.1522. J Clin Oncol. 2007. PMID: 17401012
398 results